Europe Pharmaceutical Glass Vials And Ampoules Market

Europe Pharmaceutical Glass Vials And Ampoules Market Analysis

The Europe Pharmaceutical Glass Vials And Ampoules Market size is worth USD 0.84 Billion in 2025, growing at an 5.42% CAGR and is forecast to hit USD 1.16 Billion by 2031.

• Glass has long been the preferred material in Europe's pharmaceutical packaging industry, ensuring the safe containment of medicines. Its chemical stability and inertness make it suitable for packaging a range of products, from solids and liquids to injectables and reconstitutes. Moreover, glass's resistance to temperature fluctuations is crucial for the pharmaceutical sector, where maintaining specific temperatures is often paramount. This quality becomes even more vital during processes like sterilization, freezing, or freeze-drying, which can be particularly 'stressful' for packaging.
• Glass vials, typically manufactured from borosilicate glass, serve as small containers for storing medications, whether in liquid or powder form. Borosilicate glass's resistance to thermal shock and chemical reactions ensures the stability and safety of the stored medication. These vials find common use in the pharmaceutical sector, especially for packaging vaccines, biologics, and other injectable drugs. The rising demand for safe and reliable packaging, particularly in the expanding biologics and vaccine sectors, drives the glass vial market in Europe.
• Ampoules, sealed glass capsules designed for injections, contain liquid medication. They feature a neck that can be snapped off, ensuring a single-use, sterile environment. This design is vital for preserving the efficacy and safety of injectable drugs. Widely utilized for storing and transporting sensitive medications, ampoules guarantee contamination-free storage until use. The expanding market for ampoules is fueled by the growing demand for single-dose packaging and the rising prevalence of chronic diseases necessitating injectable treatments.
• As demand for high-value parenteral drugs surges, pharmaceutical companies face mounting pressure to expedite their market entry. In October 2023, SGD Pharma unveiled an expansion of its Sterinity range, introducing new sizes to its Ready-To-Use (RTU) Type I molded glass vials. Adding 10H ml and 20H ml sizes in trays offers customers enhanced flexibility, addressing specific requests for high-quality sterile vials tailored to parenteral drugs' aseptic fill/finish.
• There's a growing trend toward recycled glass products in Europe, particularly Type II and Type III glass. These utilize materials sourced from an external supply chain and are certified for pharmaceutical use. These recycled materials regenerate through chemical and mechanical processing into glass powder, forming the foundation for a new processing cycle. Concurrently, initiatives are underway to develop low-emission furnaces, leveraging innovative technologies and industrial processes to minimize environmental impact.

Europe Pharmaceutical Glass Vials And Ampoules Market Trends

Ampoules Are Set To Hold Significant Market Share

• Ampoules, a traditional primary packaging choice for pharmaceutical drugs, are particularly favored in emerging markets. Developed concurrently with the invention of injections, ampoules serve as hermetically sealed glass containers, primarily for solutions intended for hypodermic injection.
• These glass containers ensure that pharmaceutical drugs only come into contact with inert, gas, and vapor-impermeable materials. Glass, being tamper-proof, enhances the security of the contents. Ampoule manufacturers cater to the pharmaceutical industry's specific needs, ensuring optimal packaging for each drug or application. Globally, commercial injectable solutions have predominantly been stored in glass ampoules. Their continued preference as pharmaceutical containers is attributed to their 100% glass composition, guaranteeing tamper safety, high chemical resistance, and excellent extractable and leachable profiles. The melting process used to seal ampoules further hermetically ensures their intrinsic container closure integrity.
• Beyond their primary use, ampoules safely store a variety of medications, including pain relievers, sedatives, heart and blood treatment drugs, vitamins, emergency medications, and solutions for overdose treatment.
• According to the International Trade Centre, France represents 6.5% of the global exports of glass ampoules (HS Code 701010). In 2023, France exported a total of 1,052 tons of glass ampoules. Morocco emerged as a primary destination, receiving 295 tons, followed by Spain with 149 tons. In terms of value, France's total exports amounted to USD 12,288 thousand. Breaking it down further, the United States of America imported glass ampoules worth USD 4,251 thousand, Morocco received USD 1,502 thousand, and Spain accounted for USD 1,357 thousand. The country's robust manufacturing capabilities and adherence to international quality standards have positioned it as a key player in the glass ampoule export market.
• Despite facing competition from vials and, more recently, pre-filled syringes, ampoules remain the top global choice for injectable primary packaging. Notably, there's a discernible growth in cost-sensitive markets. Furthermore, advancements in ampoule packaging, sustainability initiatives, and manufacturing innovations like automation and robotics are key drivers for the market's expansion.
• In January 2024, Germany's SCHOTT Pharma unveiled plans to establish a new glass pharmaceutical packaging factory in Serbia. The facility, located in a Serbian city, intends to focus on producing glass ampoules, syringes, and containers for injectable solutions, catering primarily to Western and Eastern European markets. This investment is poised to substantially impact the local economy, heralding new opportunities for enhancing the labor market.

Germany is Anticipated to Account For The Major Market Share

• Germany, recognized as one of the world's premier locations for clinical trials, stands out in Europe as the foremost hub for pharmaceutical innovation, as highlighted by Germany Trade and Invest (GTAI). Germany is the largest exporter of medicinal products and holds a prominent position among the top pharmaceutical producers globally. The country is particularly noted for its production of glass ampoules and vials, which are essential for the safe and effective packaging of pharmaceuticals. German manufacturers have a long-standing tradition of excellence in glass production, ensuring that their products meet the highest quality and safety standards.
• With its focus on innovative drugs and tailored therapies, the German market presents lucrative prospects for pharmaceutical companies. The demand for high-quality glass ampoules and vials has surged, driven by the need for reliable, sterile packaging solutions. German manufacturers are at the forefront of this sector, leveraging advanced technologies to produce superior glass containers that meet stringent industry standards. These manufacturers invest heavily in research and development to continuously improve their products, ensuring they remain competitive in the global market.
• In response to the industry's evolving landscape, the German government is actively deliberating a new Pharma Strategy, aiming to implement reforms that bolster the pharmaceutical sector in the country. This strategy includes measures to enhance the production capabilities of glass ampoules and vials, ensuring that Germany remains a key player in the global pharmaceutical supply chain. These reforms are expected to further improve the conditions for pharmaceutical companies operating in Germany, fostering innovation and growth in the sector. In addition, the government plans to support initiatives that promote sustainability in glass production, aligning with global environmental standards and reducing the industry's carbon footprint.
• In July 2024, SCHOTT Pharma introduced EVERIC Freeze Vials tailored for Deep-Cold Storage. SCHOTT Pharma, renowned for its pharmaceutical drug containment solutions and delivery systems, launched glass vials designed explicitly for the deep-cold storage of medications. Certain vaccines, including gene therapies and mRNA treatments, require storage and transport at frigid temperatures, reaching as low as -80°C. Due to the intense thermal stress during freezing and thawing, conventional vials often suffer from glass breakage. This vulnerability leads to significant downtimes and potential drug losses. Manufactured in Müllheim, Germany, these innovative vials can be provided as ready-to-use (RTU) upon request and come in sizes ranging from 2 to 30 ml.
• As per preliminary figures from the Federal Association of Glass Industry, Germany produced approximately 6.92 million tons of glass and glassware in 2023, down from 7.96 million tons in 2022. The glass vials and ampoules market in Germany remains a critical segment within the broader glass industry. Germany's robust pharmaceutical research and development sector and well-established healthcare infrastructure significantly contribute to the demand for glass vials and ampoules. These components are essential for the storage and transportation of various pharmaceutical products. The high standards of healthcare services and continuous advancements in medical research drive the need for reliable, high-quality glass packaging solutions.

Europe Pharmaceutical Glass Vials And Ampoules Industry Overview

The European pharmaceutical glass vials and ampoules market is fragmented, with the presence of major players like Schott AG, Gerresheimer AG, Stevanato Group, SGD SA, and Bormioli Pharma SA. Players in the market are adopting strategies such as partnerships and acquisitions to enhance their product offerings and gain sustainable competitive advantage. These strategies help companies to expand their market presence, enhance their product portfolios, and meet the diverse needs of consumers. The continuous efforts to innovate and improve packaging solutions are expected to further propel the growth of the pharmaceutical glass vials and ampoules market.

Europe Pharmaceutical Glass Vials And Ampoules Market Leaders

Europe Pharmaceutical Glass Vials And Ampoules Market News

• May 2024: Gerresheimer Glas GmbH, an indirect subsidiary of Gerresheimer AG, inked a purchase agreement with funds advised by Triton ("Triton") to acquire Blitz LuxCo Sarl, the holding entity of the Bormioli Pharma Group ("Bormioli Pharma"). The agreed purchase price hinges on an enterprise value pegged at approximately EUR 800 million (USD 883.24 million). Bormioli Pharma's diverse portfolio encompasses pharmaceutical primary packaging crafted from both glass and plastic, alongside closure solutions, accessories, and dispensing systems. Through this acquisition, Gerresheimer bolsters its presence in Europe, particularly in Southern regions, and solidifies its stature as a premier full-service provider and global ally to the pharmaceutical and biotech sectors.
• January 2024: SGD Pharma boosted capacity for siliconized glass vials with a new line. The company inaugurated a new siliconisation operation at its Saint-Quentin Lamotte (SQLM) facility in France. By bringing glass silicification in-house, the company bolsters its already comprehensive suite of services, ensuring quicker responses, a secure supply chain, and greater flexibility in vial sizes. The newly established operation at SQLM can handle all glass types, accommodating vial sizes from 3 ml to 500 ml in both clear and amber variants, all while maintaining a high processing capacity. This treatment caters to diverse market needs, including applications in anti-infectives, parenteral nutrition, diagnostics, animal health, and oncology.